Guidelines for physicians with patients on IFNβ-1b: The use of an assay for neutralizing antibodies (NAB)

Neurology

Volumn 47, Issue 4, 1996, Pages 865-866

  Paty, D W ^a   Goodkin, D ^a   Thompson, A ^a   Rice, G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; PLACEBO;

ANTIBODY TITER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0029832046     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.4.865     Document Type: Review

References (0)